Page 206 - 2019_04-Haematologica-web

A. Radujkovic et al. References
1. Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complica- tions of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495-1502.
2. Dietrich S, Falk CS, Benner A, et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-ver- sus-host disease and response to steroid treatment. Biol Blood Marrow Transplant. 2013;19(1):22-27.
3. Tatekawa S, Kohno A, Ozeki K, et al. A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation. Biol Blood Marrow Transplant. 2016;22(9): 1573-1581.
4. Dietrich S, Okun JG, Schmidt K, et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus- host disease in the absence of statin therapy. Haematologica. 2014;99(3):541-547.
5. Rachakonda SP, Penack O, Dietrich S, et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mor- tality in patients with graft-versus-host dis- ease. J Clin Oncol. 2014;32(30):3421-3427.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20 (Suppl 12):S60-62.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endoge- nous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339 (8793):572-575.
8. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asym- metrical dimethylarginine in humans. Circulation. 2004;109(2):172-177.
9. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide syn- thase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr. 2004;134:(10 Suppl):2842S-2847S.
10. Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular dis- ease? Curr Top Med Chem. 2013;13(2):180- 200.
11. Schlesinger S, Sonntag SR, Lieb W, Maas R. Asymmetric and symmetric dimethylargi- nine as risk markers for total mortality and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. PLoS One. 2016;11(11): e0165811.
12. Zhou S, Zhu Q, Li X, et al. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Sci Rep. 2017;7:44692.
13. Schemper M, Smith TL. A note on quantify- ing follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
14. Jonckheere AR. A distribution free k-sample test against ordered alternatives. Biometrika. 1954(1-2):133-145.
thases in mammals. Biochem J. 1994;298(Pt
2):249-258.
30. Lind M, Hayes A, Caprnda M, et al.
15. Tsikas D, Bollenbach A, Hanff E, Kayacelebi
AA. Asymmetric dimethylarginine
(ADMA), symmetric dimethylarginine
(SDMA) and homoarginine (hArg): the
ADMA, SDMA and hArg paradoxes.
Cardiovasc Diabetol. 2018;17(1):1. 375.
16. Chen XM, Hu CP, Li YJ, Jiang JL. Cardiovascular risk in autoimmune disor- ders: role of asymmetric dimethylarginine. Eur J Pharmacol. 2012;696(1-3):5-11.
17. Esposito C, Grosjean F, Torreggiani M, et al. Increased asymmetric dimethylarginine serum levels are associated with acute rejec- tion in kidney transplant recipients. Transplant Proc. 2009;41(5):1570-1573.
18. Frenay AR, van den Berg E, de Borst MH, et al. Plasma ADMA associates with all-cause mortality in renal transplant recipients. Amino Acids. 2015;47(9):1941-1949.
19. Koch A, Weiskirchen R, Kunze J, et al. Elevated asymmetric dimethylarginine lev- els predict short- and long-term mortal- ity risk in critically ill patients. J Crit Care. 2013;28(6):947-953.
20. Winkler MS, Kluge S, Holzmann M, et al. Markers of nitric oxide are associated with sepsis severity: an observational study. Crit Care. 2017;21(1):189.
21. Luft T, Dietrich S, Falk C, et al. Steroid- refractory GVHD: T-cell attack within a vul- nerable endothelial system. Blood. 2011;118(6):1685-1692.
22. Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant. 2009;44(1):43-49.
23. Lindås R, Tvedt TH, Hatfield KJ, Reikvam H, Bruserud O. Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. J Transplant. 2014;2014: 404096.
24. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothe- lium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013;304(12):H1585-1597.
25. Jefferis BJ, Papacosta O, Owen CG, et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011;217(1):227-233.
26. Durpès MC, Morin C, Paquin-Veillet J, et al. PKC-β activation inhibits IL-18-binding pro- tein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res. 2015;106(2):303-313.
31. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vas- cular lesions in endothelial nitric oxide syn- thase-deficient mice: involvement of renin- angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24(9): 1682-1688.
32. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysio- logical significance of raised plasma ADMA. PLoS Med. 2005;2(10):e264.
33. Németh B, Ajtay Z, Hejjel L, et al. The issue of plasma asymmetric dimethylarginine ref- erence range - a systematic review and meta-analysis. PLoS One. 2017;12(5): e0177493.
34. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel). 2017;9(3):E92.
35. McCarty MF. Asymmetric dimethylarginine is a well established mediating risk factor for cardiovascular morbidity and mortality- should patients with elevated levels be sup- plemented with citrulline? Healthcare (Basel). 2016;4(3):E40.
36. Allerton TD, Proctor DN, Stephens JM, Dugas TR, Spielmann G, Irving BA. l-cit- rulline supplementation: impact on car- diometabolic health. Nutrients. 2018;10 (7):E921.
37. Atsuta Y, Hirakawa A, Nakasone H, et al. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1702-1709.
38. Tichelli A, Passweg J, Wójcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93 (8):1203-1210.
39. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end- organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1 Suppl 1):23-32.
40. Tichelli A, Gratwohl A. Vascular endothe- lium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21(2):139-148.
41. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20): 4715-4726.
42. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
27. Kocak H, Oner-Iyidogan Y, Gurdol F, Oner P, Esin D. Serum asymmetric dimethylarginine and nitric oxide levels in obese post- menopausal women. J Clin Lab Anal. 2011;25(3):174-178.
28. Cvetković T, Veličković-Radovanović R, Stojanović D, et al. Oxidative and nitrosative stress in stable renal transplant recipients with respect to the immunosup- pression protocol- differences or similari- ties? J Med Biochem. 2015;34(3):295-303.
29. Knowles RG, Moncada S. Nitric oxide syn-
Inducible nitric oxide synthase: good or bad? Biomed Pharmacother. 2017;93:370-
834
haematologica | 2019; 104(4)